Archives

Vanda Pharmaceuticals announces the publication of “Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis” in NEJM Evidence

B WASHINGTON, April 28, 2026 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of the original research article titled “Efficacy and Safety of Imsidolimab for Generalized…

Read MoreVanda Pharmaceuticals announces the publication of “Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis” in NEJM Evidence